肺部吸入给药系统的研究进展  

Research progress in pulmonary inhalation drug delivery system

作　　者：万妮 陈斌 李合 叶伟伦 王慧 WAN Ni;CHEN Bin;LI He;YE Wei-lun;WANG Hui(Zhuhai Livzon Microsphere Technology Co.,Ltd.,Zhuhai 519000,China)

机构地区：[1]珠海市丽珠微球科技有限公司,珠海519000

出　　处：《中国新药杂志》2021年第15期1386-1395,共10页Chinese Journal of New Drugs

基　　金：国家“重大新药创制”科技重大专项资助项目(2017ZX 09201004-018);中国博士后科学基金(2019M652950);广东省“珠江人才计划”引进第六批创新创业团队(2016ZT06Y229)。

摘　　要：肺部给药系统具有起效快、疗效好、同时减少不良反应等优点,已成为一种倍受关注的给药方式。在全球新型给药系统药物市场中,肺部吸入给药系统占有极为重要的地位,特别是在慢性阻塞性肺病和哮喘等与呼吸道相关疾病的治疗方面具有广泛的临床应用价值。本文将从吸入制剂的最新分类、美国FDA已上市产品情况和创新性产品研究进展等方面入手,对目前最新的吸入制剂进行综述,为今后肺部吸入制剂的研发创新提供思路和启发。Pulmonary inhalation drug delivery has been becoming one of most popular therapy approaches due to its advantages of quick onset of action,improved efficacy and reduced adverse drug reaction.Pulmonary drug delivery system plays an extremely important role worldwide in the fields of developing new drug delivery systems,particularly in the treatment of respiratory diseases such as chronic obstructive pulmonary disease(COPD)and asthma,which shows a promising prospect of clinical application.This review critically summarizes the latest classification of inhalable formulations,the US FDA-approved products on the market and the research progress of innovative products,aiming to provide broad ideas and new inspirations for the development of pulmonary inhalation formulations in the future.

关 键 词：肺部给药系统 美国FDA吸入产品 吸入液体制剂 吸入气雾剂 吸入粉雾剂 

分 类 号：R972.6[医药卫生—药品]